Analyst Price Targets — CRBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 29, 2025 12:49 pm | — | Mizuho Securities | $39.00 | $17.12 | TheFly | Corbus Pharmaceuticals price target raised to $39 from $32 at Mizuho |
| October 20, 2025 12:32 pm | — | Piper Sandler | $51.00 | $16.86 | TheFly | Corbus Pharmaceuticals price target raised to $51 from $35 at Piper Sandler |
| October 20, 2025 10:56 am | — | H.C. Wainwright | $40.00 | $19.32 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Corbus Pharmaceuticals (CRBP) |
| December 2, 2024 9:09 am | Biren Amin | Piper Sandler | $35.00 | $17.82 | StreetInsider | Piper Sandler Starts Corbus Pharmaceuticals (CRBP) at Overweight |
| October 21, 2024 6:17 am | Jeff Jones | Oppenheimer | $60.00 | $18.41 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) |
| September 20, 2024 1:04 pm | Kalpit Patel | B.Riley Financial | $40.00 | $19.51 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Lowered to $40 at B.Riley |
| September 13, 2024 6:52 am | Graig Suvannavejh | Mizuho Securities | $74.00 | $51.58 | StreetInsider | Mizuho Reiterates Outperform Rating on Corbus Pharmaceuticals (CRBP) |
| August 7, 2024 7:44 am | Jeff Jones | Oppenheimer | $88.00 | $48.30 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Raised to $88 at Oppenheimer |
| July 22, 2024 6:09 am | Andres Maldonado | H.C. Wainwright | $80.00 | $58.00 | TheFly | Corbus Pharmaceuticals resumed with a Buy at H.C. Wainwright |
| June 11, 2024 6:12 am | Brian Abrahams | RBC Capital | $82.00 | $43.87 | StreetInsider | Corbus Pharmaceuticals (CRBP) PT Raised to $82 at RBC Capital |
Latest News for CRBP
NORWOOD, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced that it will host an in-person and virtual KOL event at the 2026 American Society of Clinical Oncology (ASCO) annual meeting to discuss updated data from the Phase 1/2 clinical study of CRB-701 in 75 participants…
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares are down on Tuesday as the company announced broad alignment with the FDA regarding the registration path for its CRB-701 treatment.
Assenagon Asset Management S.A. increased its position in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) by 120.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 187,956 shares of the biopharmaceutical company's stock after purchasing an additional 102,609 shares
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NORWOOD, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage company focused on promising new therapies in oncology and obesity, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CRBP.
U.S. House Trading
No House trades found for CRBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.